MRNA · 10-Q · 2026Q2 · Full report

Manufacturing And Capacity

Moderna, Inc. · 2026-07-31 · Importance 16 · Surprise 6 · Matches filing data

Moderna describes its integrated manufacturing capabilities as enabling rapid clinical and commercial production at scale. The company manufactures across its mRNA platform while developing medicines in infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Under the Merck collaboration for intismeran autogene, Moderna is primarily responsible for process development and manufacturing of clinical materials, while Merck generally leads clinical trials. Moderna also operates leased manufacturing and laboratory spaces globally, including its approximately 462,000-square-foot Moderna Science Center campus in Cambridge.

Key facts

• Future minimum lease payments under non-cancelable lease agreements total minimum payments of $1,030 million as of June 30, 2026. source
• Moderna, Inc. increased production resulting in an increase in inventory of $126 million during the six months ended June 30, 2026 driven by increased production for the upcoming season. source
• Property, plant and equipment, net at June 30, 2026: $2,059 million. source
• Property, plant and equipment, net at December 31, 2025: $2,134 million. source
• Land and building and building improvements as components of property, plant and equipment included building and building improvements of $1,216 million at June 30, 2026 and $1,183 million at December 31, 2025. source
• Total property, plant and equipment (gross) as reported: $2,908 million at June 30, 2026 and $2,871 million at December 31, 2025. source
• The MSC lease commenced in the third quarter of 2023 and has a term with options for two additional seven-year extensions. source
• Our primary leased campus, the Moderna Science Center (MSC) in Cambridge, comprises approximately 462,000 square feet. source

Impact estimates